Skip to content

Altimmune ALT Depreciation

Depreciation at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD

Other financials

Income statement

See full
Revenue$26.0K+420%
Operating income-$24.2M-11.1%
Net income-$22.6M-15.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$97.6M+98.7%
Total debt$34.8M+14,092%
Total equity$284.0M+99.8%
Total assets$335.6M+113%

Cash flow

See full
Operating cash flow-$20.9M-24.4%
CapEx$21.0K
Free cash flow-$21.0M

Valuation

See full
Market cap$558.14M-2.1%
Enterprise value$495.27M-5.0%
P/S13,613.2×-24,380×

Profitability

See full
Operating margin-230,461%-82,087pp
Net margin-214,861%-76,057pp
FCF margin-17,806.8%-110,030pp

Returns & leverage

See full
Return on equity-42.7%-8.7pp
Debt / equity0.1×+0.1×
Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Altimmune's depreciation?
Altimmune (ALT) reported depreciation of $23K in Q1 2026.
How has Altimmune's depreciation changed year-over-year?
Altimmune's depreciation decreased by 20.7% year-over-year, from $29K to $23K.
What is the long-term trend for Altimmune's depreciation?
Over 3 years (2022 to 2025), Altimmune's depreciation has grown at a -39.0% compound annual growth rate (CAGR), from $493K to $112K.